Squamous Non-Small Cell Lung Cancer

Oncology
4
Pipeline Programs
5
Companies
16
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
150%
Small Molecule
150%
+ 4 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Bristol Myers Squibb
2 programs
1
Nivolumab 10 MG/ML Intravenous SolutionPhase 31 trial
NivolumabN/AMonoclonal Antibody1 trial
Active Trials
NCT02475382No Longer Available
NCT03542461Unknown125Est. Jan 2023
CT
1 program
1
AnlotinibPhase 3Small Molecule1 trial
Active Trials
NCT04073537UnknownEst. Jun 2022
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
CarboplatinPhase 35 trials
Active Trials
NCT07024784Recruiting377Est. Feb 2028
NCT03400306Withdrawn0Est. Nov 2021
NCT02470585Terminated1,140Est. Oct 2023
+2 more trials
Moderna
ModernaCAMBRIDGE, MA
1 program
1
V940Phase 21 trial
Active Trials
NCT07221474Recruiting180Est. May 2031
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
Second lineN/A1 trial
Active Trials
NCT04552535Completed200Est. May 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Chia Tai TianQing Pharmaceutical GroupAnlotinib
Bristol Myers SquibbNivolumab 10 MG/ML Intravenous Solution
AbbVieCarboplatin
AbbVieCarboplatin
AbbVieCarboplatin
ModernaV940
AbbVieCarboplatin
AbbVieCarboplatin
AbbVieCarboplatin
AbbVieCarboplatin
AbbVieCarboplatin
AbbVieCarboplatin
AbbVieCarboplatin
AbbVieCarboplatin
Boehringer IngelheimSecond line

Clinical Trials (16)

Total enrollment: 4,157 patients across 16 trials

NCT04073537Chia Tai TianQing Pharmaceutical GroupAnlotinib

Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer

Start: Oct 2019Est. completion: Jun 2022
Phase 3Unknown
NCT03542461Bristol Myers SquibbNivolumab 10 MG/ML Intravenous Solution

Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)

Start: Sep 2017Est. completion: Jan 2023125 patients
Phase 3Unknown
NCT02470585AbbVieCarboplatin

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Start: Jul 2015Est. completion: Oct 20231,140 patients
Phase 3Terminated
NCT02106546AbbVieCarboplatin

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Start: Apr 2014Est. completion: Nov 2019970 patients
Phase 3Completed
NCT02163694AbbVieCarboplatin

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Start: Apr 2014Est. completion: Jan 2024513 patients
Phase 3Completed
NCT07221474ModernaV940

A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

Start: Dec 2025Est. completion: May 2031180 patients
Phase 2Recruiting
NCT07024784AbbVieCarboplatin

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Start: Jul 2025Est. completion: Feb 2028377 patients
Phase 2Recruiting
NCT01506609AbbVieCarboplatin

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

Start: Jan 2012Est. completion: Sep 2020294 patients
Phase 2Completed
NCT02412371AbbVieCarboplatin

A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)

Start: Apr 2015Est. completion: Aug 201948 patients
Phase 1/2Terminated
NCT02289690AbbVieCarboplatin

Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

Start: Oct 2014Est. completion: Apr 2019221 patients
Phase 1/2Completed
NCT03400306AbbVieCarboplatin

A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer

Start: Nov 2021Est. completion: Nov 20210
Phase 1Withdrawn
NCT02483104AbbVieCarboplatin

Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer

Start: Jul 2015Est. completion: Jul 20169 patients
Phase 1Completed
NCT02033551AbbVieCarboplatin

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

Start: Dec 2013Est. completion: Sep 201647 patients
Phase 1Completed
NCT00654758AbbVieCarboplatin

A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC)

Start: Dec 2007Est. completion: May 201033 patients
Phase 1Completed
NCT02475382Bristol Myers SquibbNivolumab

Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen

N/ANo Longer Available
NCT04552535Boehringer IngelheimSecond line

A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung

Start: May 2020Est. completion: May 2020200 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 4,157 patients
5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)